Highlights from ASH 2016: adaptive therapy and reducing toxicity

Highlights from ASH 2016: adaptive therapy and reducing toxicity

VJHemOnc

2 years
908 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Raúl Córdoba, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, discusses his two main highlights from ASH 2016. The first highlight includes learning more and more about adaptive therapy in Hodgkins lymphoma. For example, if interim response after two cycles of chemotherapy leads to a PET-CT negative, we can decrease the regimen in order to decrease toxicity, without affecting the outcome. If the patient remains PET-positive after two cycles, we would have to increase the dose level of chemotherapy in order to overcome this bad prognosis factor. Another field of increasing interest is the treatment of elderly patients, particularly those with mantle-cell lymphoma. Experts are working towards better identifying frailty and co-morbidity in elderly lymphoma patients in order to receive a better outcome with lower toxicity. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Up Next Autoplay
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
1 Views
Cancer-News 41 minutes
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
5 Views
kidneycancer 19 hours
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
4 Views
kidneycancer 20 hours
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
3 Views
CURC 22 hours
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 22 hours
ProVent Trial Changing AS Landscape @UrologyUS
ProVent Trial Changing AS Landscape @UrologyUS
Category: Prostate Cancer
3 Views
CURC 22 hours
Current Treatment Options in the ProVent Trial
Current Treatment Options in the ProVent Trial
Category: Prostate Cancer
3 Views
CURC 23 hours
Phase 3 ProVent Clinical Trial @UrologyUS
Phase 3 ProVent Clinical Trial @UrologyUS
Category: Prostate Cancer
4 Views
CURC 23 hours
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
7 Views
kidneycancer 2 days
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
10 Views
kidneycancer 2 days